The pharmacodynamic effect of amoxicillin and danofloxacin against Salmonella typhimurium in an in-vitro pharmacodynamic model

Research in Veterinary Science

Volumn 68, Issue 3, 2000, Pages 261-264

  Lindecrona, R H ^a,b   Friis, C ^a   Aarestrup, F M ^b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b TECHNICAL UNIVERSITY OF DENMARK   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; DANOFLOXACIN;

ANIMAL SALMONELLOSIS; ARTICLE; COMPARTMENT MODEL; DRUG CONCENTRATION; DRUG HALF LIFE; MINIMUM INHIBITORY CONCENTRATION; PHARMACODYNAMICS; SALMONELLA TYPHIMURIUM;

EID: 0033930026     PISSN: 00345288     EISSN: None     Source Type: Journal    
DOI: 10.1053/rvsc.2000.0374     Document Type: Article

References (26)

1. AGERSØ H. & FRIIS C. (1998) Bioavailability of amoxicillin in pigs. Journal of Veterinary Pharmacology and Therapeutics 21, 41-46
2. BAQUERO F. & NEGRI M.C. (1997) Strategies to minimize the development of antibiotic resistance. Journal of Chemotherapy 9, (suppl. 3) 29-37
3. BLASER J. & ZINNER S.H. (1987) In vitro models for the study of antibiotic activities. Progress Drug Research 31, 349-381
4. BLASER J., STONE B.B., GRONER M.C. & ZINNER S.H. (1987) Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance. Antimicrobial Agents and Chemotherapy 31, 1054-1060
5. CHAMBERS S.T., PEDDIE B.A., ROBSON R.A., BEGG E.J. & BOSWELL D.R. (1991) Antimicrobial effects of lomefloxacin in-vitro. Journal of Antimicrobial Chemotherapy 27, 481-489
6. CRAIG W.A. (1995) Antibiotic selection factors and description of a hospital-based outpatient antibiotic therapy program in the USA. European Journal of Clinical Microbiology and Infectious Disease 14, 636-642
7. CRAIG W.A. (1996) Antimicrobial resistance issues of the future. Diagnostic Microbiology and Infectious Disease 25, 213-217
8. CRAJG W.A. & EBERT S.C. (199I) Killing and regrowth of bacteria in vitro: A review. Scandinavian Journal of Infectious Disease Suppl.74. 63-70
9. DRUSANO G.L. (1991) Human pharmacodynamics of beta-lactams, aminoglycosides and their combination. Scandinavian Journal of Infectious Disease suppl.74, 235-248
10. DRUSANO G.L. & CRAIG W.A. (1997) Relevance of pharmacokinetics and pharmacodynamics in the selection of antibiotics for respiratory tract infections. Journal of Chemotherapy 9, (suppl. 3) 38-44
11. DRUSANO G.E., JOHNSON D.E., ROSEN M. & STANDIFORD H.C. (1993) Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis. Antimicrobial Agents and Chemotherapy 37, 483-490
12. DUDLEY M.N., MANDLER H.D., GILBERT D., ERICSON J., MAYER K.H. & ZINNER S.H. (1987) Pharmacokinetics and pharmacodynamics of intravenous ciprofloxacin (studies in vivo and in an in vitro dynamic model). American Journal of Medicine 82, 363-368
13. DUDLEY M.N., BLASER J., GILBERT D., MAYER K.H. & ZINNER S.H. (1991) Combination therapy with ciprofloxacin plus azlocillin against Pseudomonas aeruginosa: Effect of simultaneous versus staggered administration in an in-vitro model of infection. Journal of infectious Disease 164, 499-506
14. FORREST A., NIX D.E., BALLOW C.H., GOSS T.F. BIRMINGHAM M.C. & SCHENTAG J.J. (1993) Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrobial Agents and Chemotherapy 37, 1073-1081
15. FORREST A., CHODOSH S., AMANTEA M.A., COLLINS D.A. & SCHENTAG J.J. (1997) Pharmacokinetics and pharmacodynamics of oral grepafloxacin in patients with acute bacterial exacerbations of chronic bronchitis. Journal of Antimicrobial Chemotherapy 40, (suppl. A) 45-57
16. FRIIS C. (1993) Penetration of danofloxacin into the respiratory tract tissues and secretions in calves. American Journal of Veterinary Research 54, 1122-1127
17. FRIIS C. & NIELSEN J.P. (1997) Penetration of danofloxacin into the respiratory tract tissues and secretions in healthy and in Actinobacillus pleuropneumoniae infected pigs. Proceedings of the 7th EAVPT Congress, Madrid, Spain. Journal of Veterinary Pharmacology and Therapeutics 20, suppl. 1, 108-109
18. GIBALDI M. & PERRIER D. (1982) Pharmacokinetics. 2nd ed. Pp. 409-417. Marcel Dekker, Inc., New York
19. KANG S.L., RYBAK M.J., MCGRATH B.J., KAATZ G.W. & SEO S.M. (1994) Pharmacodynamics of levofloxacin, ofloxacin, and ciprofloxacin, alone and in combination with rifampin against methicillin susceptible and -resistant Staphylococcus aureus in an in vitro infection model. Antimicrobial Agents and Chemotherapy 38, 2702-2709
20. LEGGETT J.E., EBERT S.C., FANTIN B. & CRAIG W.A. (1991) Comparative dose-effect relations at several dosing intervals for beta-lactam, aminoglycoside and quinolone antibiotics against gram-negative bacilli in murine thigh-infection and pneumonitis models. Scandinavian Journal of Infectious Disease suppl.74. 179-184
21. LINDECRONA R.H., FRIIS C. & JENSEN N.E. (1999) The pharmacodynamic effect of amoxicillin and danofloxacin against Actinobacillus pleuropneumoniae in an in vitro pharmacodynamic model. Research in Veterinary Science, 67, 93-97
22. MADARAS-KEELY K.J., OSTERGAARD B.E., BAEKER HOVDE E. & ROTSCHAFER J.C. (1996) Twenty-four-hour area under the concentration-time curve/MIC ratio as a generic predictor of fluoroquinolone antimicrobial effect by using three strains of Pseudomonas aeruginosa and an in vitro pharmacodynamic model. Antimicrobial Agents and Chemotherapy 40, 627-632
23. MARCHBANKS C.R., MCKIEL J.R., GILBERT D.H., ROBILLARD N.J., PAINTER B., ZINNER S.H. & DUDLEY M.N. (1993) Dose ranging and tractionation of intravenous ciprofloxacin against Pseudomonas aeruginosa and Staphylococcus aureus in an in-vitro model of infection. Antimicrobial Agents and Chemotherapy 37, 1756-1763
24. MEINEN J.B., McCLURE J.T. & ROSIN E. (1995) Pharmacokinetics of enrofloxacin in clinically normal dogs and mice and drug pharmacodynamics in neutropenic mice with Escherichia coli and staphylococcal infections. American Journal of Veterinary Research 56, 1219-1224
25. NCCLS. (1997) Performance standards for antimicrobial disk and dilution susceptibility tests for bacteria isolated from animals. Document M31-P, vol. 1, no. 1
26. PALMER S.M. & RYBAK M.J. (1996) Pharmacodynamics of once-or twice-daily levofloxacin versus vancomycin, with or without rifampin against Staphylococcus aureus in an in vitro model with infected platelet-fibrin clots. Antimicrobial Agents and Chemotherapy 40, 701-705